Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Macupatide
LY3532226 · 6 trials · 4 indications
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
PD: AUC60-120min of plasma glucagon during the insulin-induced hypoglycemia
Change from Baseline in Total cDI
| Arm | Type | Description |
|---|---|---|
| Macupatide Dose 1 | EXPERIMENTAL | Participants will receive macupatide subcutaneously (SC) |
| Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 2 + Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Macupatide (Macupatide + Eloralintide Placebo) | EXPERIMENTAL | Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC |
| Eloralintide (Elorlintide + Macupatide Placebo) | EXPERIMENTAL | Participants will be administered eloralintide SC and macupatide placebo SC |
| Macupatide + Eloralintide | EXPERIMENTAL | Participants will be administered eloralintide SC and macupatide SC |
| Placebo (Macupatide Placebo + Elorlintide Placebo) | PLACEBO_COMPARATOR | Participants will be administered eloralintide placebo SC and macupatide placebo SC |
| Macupatide ＋ placebo | EXPERIMENTAL | Macupatide and placebo administered subcutaneously (SC) |
| Eloralintide + placebo | EXPERIMENTAL | Eloralintide and placebo administered SC |
| Macupatide Dose A + Eloralintide | EXPERIMENTAL | Macupatide and Eloralintide administered SC |
| Macupatide Dose B + Eloralintide | EXPERIMENTAL | Macupatide and Eloralintide administered SC |
| LY3532226 (Part A) | EXPERIMENTAL | LY3532226 administered subcutaneously (SC) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part B) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part C) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part C) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 | EXPERIMENTAL | - |
| LY3532226 + Dulaglutide (Part A) | EXPERIMENTAL | LY3532226 administered subcutaneously (SC) followed by dulaglutide administered SC. |
| Placebo + Dulaglutide (Part A) | PLACEBO_COMPARATOR | Placebo administered SC followed by dulaglutide administered SC. |
| Dulaglutide + Placebo (Part B) | ACTIVE_COMPARATOR | Dulaglutide administered SC in combination with placebo given SC. |
| LY3532226 + Dulaglutide (Part B) | EXPERIMENTAL | LY3532226 administered SC in combination with Dulaglutide given SC. |
| LY3532226 + Placebo (Part B) | EXPERIMENTAL | LY3532226 administered SC in combination with placebo given SC. |
| Name | Type | Description |
|---|---|---|
| Macupatide | DRUG | Administered SC |
| Eloralintide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Macupatide Placebo | DRUG | Administered SC |
| Eloralintide Placebo | DRUG | Administered SC |
| LY3532226 | DRUG | Administered SC |
| Dulaglutide | DRUG | Administered SC. |
Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have ...
LY3532226 is an investigational small molecule being developed by Eli Lilly and Company for metabolic conditions, including type 1 diabetes, type 2 diabetes, and obesity. It has been studied in Phase 1 clinical trials and is not yet approved for any indication.
LY3532226 is being studied for the treatment of type 1 diabetes mellitus, type 2 diabetes mellitus, and obesity. All clinical testing to date has been in Phase 1 trials, so the drug remains investigational and has no approved use.
LY3532226 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 studies conducted in participants with obesity, type 1 diabetes, and type 2 diabetes.
LY3532226 is in Phase 1 clinical development. Three Phase 1 trials have been completed: one in obesity, one in type 1 diabetes, and one in type 2 diabetes. The drug is investigational and has not been approved by the FDA.
LY3532226 has been evaluated in three completed Phase 1 trials: NCT06557356 in participants with obesity, NCT05887999 in participants with type 1 diabetes, and NCT05407961 in participants with type 2 diabetes. These studies enrolled participants in the United States, Singapore, and Germany.
The LY3532226 Phase 1 program enrolled participants across three completed studies. NCT06557356 enrolled 132 participants with obesity, NCT05407961 enrolled 90 participants with type 2 diabetes, and NCT05887999 enrolled 30 participants with type 1 diabetes.